Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R A Blake

Showing results (11-20 of 12) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 12 results.
Anti-Cancer Drug Design|July 11, 2000
Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agentD B Mendel, A D Laird, B D Smolich, et al.
Cancer Research|August 17, 2000
SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumorsA D Laird, P Vajkoczy, L K Shawver, et al.
Pageof 2

Showing results (11-20 of 12) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 12 results.
Anti-Cancer Drug Design|July 11, 2000
Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agentD B Mendel, A D Laird, B D Smolich, et al.
Cancer Research|August 17, 2000
SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumorsA D Laird, P Vajkoczy, L K Shawver, et al.
Pageof 2